| Literature DB >> 34394293 |
Abstract
BACKGROUND: IgA nephropathy (IgAN) is most common primary glomerulopathy. There are variations in prevalence of IgAN and its clinical features in different studies from India. AIM: To summarize overall scenario of IgAN in India.Entities:
Keywords: IgA Nephropathy; India; histomorphology; prevalence
Mesh:
Substances:
Year: 2021 PMID: 34394293 PMCID: PMC8356571 DOI: 10.4314/ahs.v21i1.21
Source DB: PubMed Journal: Afr Health Sci ISSN: 1680-6905 Impact factor: 0.927
Figure 1Study selection flow diagram
Figure 2Subgrouping of the 49 studies in four
Frequencies/prevalence (%) of IgA nephropathy in India
| S. | Reference | Year | Study population | Prevalence of |
| 1. | Chacko et al | 2011 | C, A | 8.6 |
| 2 | Ganesh et al | 2018 | C, A | 21.6 |
| 3 | Siddappa S | 2011 | A | 7.8 |
| 4 | Das et al | 2015 | A, C | 7.5 |
| 5 | Agrawal et al | 2017 | A | 2.6 |
| 6 | Mittal et al | 2012 | A | 8.1 |
| 7 | Chandrika et al | 2009 | A, C | 14.2 |
| 8 | Ramakrishan | 2016 | A | 11.5 |
| 9 | Chacko et al, | 2007 | A,C | 32 |
| 10 | Vanikar et al, | 2005 | A | 16.5 |
| 11. | Bhuyan et al | 1992, 87 | A,C | 7.24 |
| 12. | Tiwari et al | 2016 | A,C | 14.3 |
| 13 | Chowdary et al | 2018 | A | 42.0 |
| 14 | Dhanapriya et al | 2018 | A | 5 |
| After pooling the data total prevalence/frequencies |
| |||
| C-children, A-Adult, | ||||
Clinical and Laboratory features of Primary IgA nephropathy, IgA vasculitis nephritis (HSP), IgA dominant nephritis and Secondary IgAN
| S.No. | Main clinical features | Primary IgA | IgA vasculitis | IgA dominant | Secondary |
| 1. | Mean age (years) | 31.7±13.8 | 37.5±15.8 | 48.6±21.3 | 27.2±16.7 |
| 2. | Male : female | 1.93:1 | 1.07:1 | 1.64:1 | 2:1 |
| 3. | Asymptomatic urinary | 5.5 | 1.4 | 0 | 9.5 |
| 4. | Macroscopic hematuria(%) | 5.1 | 0.44 | 40.94 | 35.71 |
| 5. | Microscopic hematuria(%) | 49.6 | 44.49 | 15.64 | 59.57 |
| 6. | Subnephrotic proteinuria | 42.1 | 29.42 | 23.29 | 52.38 |
| 7 | Nephrotic range proteinuria | 16.04 | 4.44 | 76.88 | 47.61 |
| 8. | Loin or abdominal pain(%) | 1.8 | 61.72 | 0 | 4.7 |
| 9. | Hypertension(%) | 25.8 | 18.39 | 35.5 | 47.61 |
| 10. | Infection-related | 10.3 | 19.14 | 47.05 | 4.7 |
| 11. | Skin Rashes(%) | 0 | 99.24 | 0 | 0 |
| 12. | GIT manifestation(%) | 0 | 54.83 | 5.8 | 0 |
| 13. | Arthritis/arthralgia(%) | 0 | 78.58 | 0 | 0 |
| 14. | Duration of symptoms | 5.40±3.2 | 3.91±0.59 | 2.87±1.84 | 2.81±3.9 |
| 15. | Raised serum creatinine | 3.04±2.6 | 0.9±0 | 3.21±20 | 3.5±3.9 |
| 16. | Reduced e-GFR | 59.54±19.3 | - | 63.6±0 | 78±0 |
| 17. | 24 h urine protein (g/d) | 2.6±1.5 | 3.2±0 | 3.5±0.2 | 4.7±2.3 |
| 18. | Serum C3 level reduced (%) | 0 | 0.06 | 88.47 | 0 |
Histomorphology (MEST & Haas's classification, Immunofluorescences and Electron microscopic findings in primary IgA nephropathy, IgA vasculitis nephritis (HSP), IgA dominant nephritis and Secondary IgAN
| S.No. | Types IgAN | Investigations | |||||||||||
| Histomorphology(%) | Immunofluorescence (%) | Electron microscopy(%) | |||||||||||
| MEST-C | Haas's | Skin | IgG | IgA | IgM | C3 | F.H. | MeD | SubEnD | SubEpD | Both | ||
| Renal biopsy | |||||||||||||
| 1. | Primay IgAN | Me- | Cl I -11.1 | - | 1.6 |
| 4.5 | 4.6 | 0.2 |
| 0.58 | 0 |
|
| 2. | IgAVN | Me- | - | LC- | 0 |
| 0 |
| 0 | - | - | - | - |
| 3. | IgADN | Me-29.4 | - | - | 12.2 | 100 | 1 |
| 0 | 0 | 5.8 |
| 5.8 |
| 4. | Secondary | Me- | - | - | 16.6 |
| 5.9 |
| 0 | 9.5 | 0 | 4.7 | 0 |
Me-Mesangial proliferation, En-Endocapillary proliferation, SG-Segmental Glomerulosclerosis, C1- <25% Cellular/fibrocellular crescent, C2- >25%Cellular/Fibrocellular crescent, T0- ≤25%TA/IF T1- 26% to 50% TA/IF, T2->50%TA/IF, N-Normal, Cl- Class, MeD-mesangial deposition, SubEnD-subenothelial deposition, SubepD-subepithelial deposition, Both-MeD+EnD, ,HistoM-histomorphology, LC- leukocytoclastic vasculitis ,F.H.-Full House